Advertisement

Survival in Patients with High-Grade Colorectal Neuroendocrine Carcinomas: The Role of Surgery and Chemotherapy

  • Adam C. FieldsEmail author
  • Pamela Lu
  • Benjamin M. Vierra
  • Frances Hu
  • Jennifer Irani
  • Ronald Bleday
  • Joel E. Goldberg
  • Garrett M. Nash
  • Nelya MelnitchoukEmail author
Colorectal Cancer
  • 39 Downloads

Abstract

Background

Colorectal neuroendocrine tumors are a rare malignancy, yet their incidence appears to be increasing. The optimal treatment for the high-grade subset of these tumors remains unclear. We aimed to examine the relationship between different treatment modalities and outcomes for patients with high-grade neuroendocrine carcinomas (HGNECs) of the colon and rectum.

Methods

The National Cancer Database (2004–2015) was used to identify patients diagnosed with colorectal HGNECs. The primary outcome was overall survival. A Cox Proportional hazard model was used to identify risk factors for survival.

Results

Overall, 1208 patients had HGNECs; 452 (37.4%) patients had primary tumors of the rectum, and 756 (62.5%) patients had primary tumors of the colon. A total of 564 (46.7%) patients presented with stage IV disease. The median survival was 9.0 months [95% confidence interval (CI) 8.2–9.8]. In multivariable analysis, surgical resection [hazard ratio (HR) 0.54, 95% CI 0.44–0.66; p < 0.001], chemotherapy (HR 0.74, 95% CI 0.69–0.79; p < 0.001), and rectum as the primary site of tumor (HR 0.62, 95% CI 0.51–0.76; p < 0.001) were associated with better overall survival, while older age (HR 1.01, 95% CI 1.00–1.01; p = 0.02) and the presence of metastatic disease (HR 3.34, 95% CI 2.69–4.15; p < 0.001) were associated with worse survival.

Conclusions

Patients with colorectal HGNECs selected for chemotherapy and surgical resection of the primary tumor demonstrated better overall survival than those managed without resection. Patients who were able to undergo systemic chemotherapy may benefit from potentially curative resection of the primary tumor.

Notes

Author Contributions

All authors made substantial contributions to the design of the work, drafted the work, approved the final version submitted for publication, and agreed to be accountable for all aspects of the work.

Disclosures

None. No grant support or financial relationships were received for this work.

References

  1. 1.
    Leoncini E, Boffetta P, Shafir M, Aleksovska K, Boccia S, Rindi G. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine. 2017;58(2):368–79.CrossRefGoogle Scholar
  2. 2.
    Shafqat H, Ali S, Salhab M, Olszewski AJ. Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis. Dis Colon Rectum 2015;58(3):294–03.CrossRefGoogle Scholar
  3. 3.
    Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120(18):2814–23.CrossRefGoogle Scholar
  4. 4.
    Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol. 2017;29:11–16.CrossRefGoogle Scholar
  5. 5.
    Shia J, Tang LH, Weiser MR, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol. 2008;32(5):719–31.CrossRefGoogle Scholar
  6. 6.
    Bernick PE, Klimstra DS, Shia J, et al. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum. 2004;47(2):163–69.CrossRefGoogle Scholar
  7. 7.
    Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–60.CrossRefGoogle Scholar
  8. 8.
    Brenner B, Shah MA, Gonen M, Klimstra DS, Shia J, Kelsen DP. Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer. 2004;90(9):1720–26.CrossRefGoogle Scholar
  9. 9.
    Walenkamp AM, Sonke GS, Sleijfer DT. Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev. 2009;35(3):228–36.CrossRefGoogle Scholar
  10. 10.
    Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS Consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186–94.CrossRefGoogle Scholar
  11. 11.
    Smith JD, Reidy DL, Goodman KA, Shia J, Nash GM. A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum. Ann Surg Oncol. 2014;21(9):2956–62.CrossRefGoogle Scholar
  12. 12.
    Chung TP, Hunt SR. Carcinoid and neuroendocrine tumors of the colon and rectum. Clin Colon Rectal Surg. 2006;19(2):45–8.CrossRefGoogle Scholar
  13. 13.
    Conte B, George B, Overman M, et al. High-grade neuroendocrine colorectal carcinomas: a retrospective study of 100 patients. Clin Colorectal Cancer. 2016;15(2):e1–e7.CrossRefGoogle Scholar
  14. 14.
    Aytac E, Ozdemir Y, Ozuner G. Long term outcomes of neuroendocrine carcinomas (high-grade neuroendocrine tumors) of the colon, rectum, and anal canal. J Visc Surg. 2014;151(1):3–7.CrossRefGoogle Scholar
  15. 15.
    Winchester DP, Stewart AK, Phillips JL, Ward EE. The national cancer data base: past, present, and future. Ann Surg Oncol. 2010;17(1):4–7.CrossRefGoogle Scholar
  16. 16.
    Ahlman H, Nilsson O, McNicol AM, et al. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology. 2008;87(1):40–46.CrossRefGoogle Scholar
  17. 17.
    Balasubramanyam S, O’Donnell BP, Musher BL, Jhaveri PM, Ludwig MS. Evaluating treatment patterns for small cell carcinoma of the colon using the national cancer database (NCDB). J Gastrointest Cancer. 2018.  https://doi.org/10.1007/s12029-018-0054-y.Google Scholar
  18. 18.
    Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77.CrossRefGoogle Scholar
  19. 19.
    Yamaguchi T, Machida N, Morizane C, et al. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 2014;105(9):1176–81.CrossRefGoogle Scholar
  20. 20.
    Hung SS. Small cell carcinoma of the colon. A case report and literature review. J Clin Gastroenterol. 1989;11(3):335–39.CrossRefGoogle Scholar
  21. 21.
    Arnold R. Endocrine tumours of the gastrointestinal tract Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol. 2005;19(4):491–05.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Adam C. Fields
    • 1
    Email author
  • Pamela Lu
    • 1
    • 2
  • Benjamin M. Vierra
    • 1
  • Frances Hu
    • 1
  • Jennifer Irani
    • 1
  • Ronald Bleday
    • 1
  • Joel E. Goldberg
    • 1
  • Garrett M. Nash
    • 3
  • Nelya Melnitchouk
    • 1
    • 2
    Email author
  1. 1.Department of Surgery, Division of Colorectal Surgery, Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA
  2. 2.Center for Surgery and Public Health, Department of Surgery, Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA
  3. 3.Memorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations